Condition

Refractory Leukemia clinical trials and research

• 8Clinical trials
• 3Countries

Newest Refractory Leukemia clinical trials

All recruiting trials (8)

• Triple-drug approach for AML using eganelisib with azacitidine and venetoclax

  This early-stage trial tests whether adding eganelisib to azacitidine and venetoclax can be safe and show signs of benefit in adults with acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07439211

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

• Chemotherapy plus HLA-mismatched G-CSF mobilized peripheral blood cells as a bridge to allogeneic stem cell transplant for relapsed or refractory leukemia

  This trial will test whether adding an HLA-mismatched G-CSF mobilized peripheral blood mononuclear cell infusion to chemotherapy can safely help people with relapsed or refractory leukemia reach an allogeneic stem cell transplant.

  Recruiting Phase 1 Beijing 302 Hospital · Beijing · NCT07297173

• Roginolisib with venetoclax and rituximab for relapsed or refractory CLL

  This trial will test whether adding roginolisib to the standard venetoclax plus rituximab treatment helps people with relapsed or refractory CLL get deeper and longer remissions.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06644183

• Chemotherapy and Reduced Intensity Conditioning for Refractory Acute Myeloid Leukemia

  This study is testing a new treatment plan that combines a special chemotherapy with a gentler conditioning method to see if it helps people with hard-to-treat acute myeloid leukemia feel better and live longer.

  Recruiting at 3 sites Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 2 other locations · NCT05870995

• Olverembatinib plus APG-2575 for children with relapsed or refractory Philadelphia-positive ALL

  This study tests whether a combination of olverembatinib and APG-2575, with dexamethasone, is safe and potentially effective in children with relapsed or refractory Ph+ ALL who have already tried other TKIs.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Hefei, Anhui and 3 other locations · NCT05495035

• Combining Venetoclax, Chidamide, and Azacitidine for treating relapsed AML

  This study is testing a new combination of three drugs to see if it can help people with relapsed acute myeloid leukemia feel better and achieve longer-lasting results.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT05305859

• Improving diagnosis of hematological diseases using advanced sequencing techniques

  This study is testing new genetic sequencing methods to help doctors better diagnose blood disorders in patients who currently have unclear or unusual symptoms.

  Recruiting Munich Leukemia Laboratory · Munich · NCT05046444

Related topics

Quick answers

How many Refractory Leukemia clinical trials are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in China (4 trials), United States (3 trials), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 1/2: 2, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →